Nadifloxacin-d5

[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216.|[2]Jacobs, M.R. and P.C. Appelbaum, Nadifloxacin: a quinolone for topical treatment of skin infections and potential for systemic use of its active isomer, WCK 771. Expert Opin Pharmacother, 2006. 7 (14) : p. 1957-66.|[3]Choudhury, S., et al., Efficacy and safety of topical nadifloxacin and benzoyl peroxide versus clindamycin and benzoyl peroxide in acne vulgaris: A randomized controlled trial. Indian J Pharmacol, 2011. 43 (6) : p. 628-31.|[4]Vogt K, et al. Comparative activity of the topical quinolone OPC-7251 against bacteria associated with acne vulgaris. European Journal of Clinical Microbiology and Infectious Diseases, 1992, 11 (10) : 943-945. |[5]Kuwahara K, et al. Nadifloxacin, an antiacne quinolone antimicrobial, inhibits the production of proinflammatory cytokines by human peripheral blood mononuclear cells and normal human keratinocytes. J Dermatol Sci. 2005 Apr;38 (1) :47-55.|[6]Yamakawa T, et al. In vitro and in vivo antibacterial activity of T-3912, a novel non-fluorinated topical quinolone. J Antimicrob Chemother. 2002 Mar;49 (3) :455-65.